IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
出版年份 2020 全文链接
标题
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-05-18
DOI
10.1111/bjh.16710
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
- (2019) Michael Leisch et al. Cancers
- Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use
- (2019) Valeria Santini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The role of IDO, IL-10 and TGF-β in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma
- (2018) Ruonan Yang et al. JOURNAL OF MEDICAL VIROLOGY
- DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4+CD25high FOXP3+ Regulatory T Cells but Does Not Affect Their Suppressive Capacity
- (2018) Sija Landman et al. Journal of Immunology Research
- A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
- (2018) Rami S. Komrokji et al. Clinical Lymphoma Myeloma & Leukemia
- Immunological effects of hypomethylating agents
- (2017) Katherine E. Lindblad et al. Expert Review of Hematology
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
- (2016) Lisa Pleyer et al. Journal of Hematology & Oncology
- Myelodysplastic syndromes: Contemporary review and how we treat
- (2015) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia
- (2015) Jose F. Falantes et al. Clinical Lymphoma Myeloma & Leukemia
- Digging deep into “dirty” drugs – modulation of the methylation machinery
- (2015) Lisa Pleyer et al. DRUG METABOLISM REVIEWS
- Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment
- (2014) W. Ling et al. CANCER RESEARCH
- Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target
- (2014) Kongfei Li et al. Journal of Translational Medicine
- Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
- (2014) Cecile Bally et al. LEUKEMIA RESEARCH
- A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2013) Xavier G. Thomas et al. Clinical Lymphoma Myeloma & Leukemia
- Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification
- (2013) Céline Berthon et al. LEUKEMIA RESEARCH
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Exploring the mechanism of tryptophan 2,3-dioxygenase
- (2008) Sarah J. Thackray et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
- (2008) M. E.D. Chamuleau et al. HAEMATOLOGICA
- Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ
- (2008) Selim Corm et al. LEUKEMIA RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started